Overview

Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Status:
Completed

Trial end date:
2013-04-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the long-term safety and tolerability of inhaled aclidinium bromide/formoterol in patients with moderate to severe, stable chronic obstructive pulmonary disease (COPD).

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Bromides
Formoterol Fumarate